Capital Advisors Ltd’s ALX Oncology ALXO Stock Holding History

Capital Advisors Ltd’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-79	Closed	–	–	1350
2024 Q2	$0	Hold	79	–	–	﹤0.01%	1359
2024 Q1	$1K	Hold	79	–	–	﹤0.01%	1108
2023 Q4	$1K	Buy	+79	New	+$750	﹤0.01%	1079

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Advisors Ltd's ALXO Position: Q3 2024 in Review

Capital Advisors Ltd sold out of ALX Oncology (ALXO) in Q3 2024, closing a stake of 79 shares.

Capital Advisors Ltd first reported a position in ALXO in Q4 2023 and held it in 3 quarters. The position peaked at $1K in Q1 2024. 92 funds tracked by Wall St. Rank hold ALXO as of Q3 2024.

Capital Advisors Ltd reported no remaining ALX Oncology position as of Q3 2024 after selling out during the quarter.
Capital Advisors Ltd sold 79 ALX Oncology shares in Q3 2024.
Capital Advisors Ltd first reported a position in ALX Oncology in Q4 2023 and held it in 3 quarters.
Capital Advisors Ltd's ALX Oncology position peaked at $1K in Q1 2024.
92 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2024.

Based on Capital Advisors Ltd's 13F filing for Q3 2024, filed 24 Oct 2024.